|
|
|
| home > ict > Summer 2006 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. ICT provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of ICT |
 |
| |
|
|
Pam Barnacal introduces the inaugural ICT in her Editor’s Letter
|
|
|
|
| Are commercial concerns interfering with standards in the pharmaceutical industry? As public attitudes come increasingly close to this standpoint, Dr Faiz Kermani at Chiltern International looks at what industry can do to turn opinions around, in Public Concerns and Clinical Research |
|
|
| Clinical trials in children are an ethical, regulatory and commercial minefield; Dr Richard Tiner at the Association of the British Pharmaceutical Industry guides us through how the landscape is set to change, in Medicating Minors: The Present and the Future |
|
|
| Following the UK Government's 2006 budget announcements, now is a good time to revisit the provisions of the UK's research and development tax relief. David O'Keeffe and Mark Hobbs at KPMG's Research & Development Tax Relief Group elucidate, in Money-Back Guarantee |
|
|
|
|
| Conducting clinical trials within the EU becomes even more complicated for non-EU companies. In Foreign Policy, Nicola Maguire and George Pickering at Reed Smith separate the Clinical Trial Directive, the Data Protection Directive and the national legislation implementing them |
|
|
| In Nordic Compassion, Hilde Kloster Smerud, Stian Brekke and Knut T Smerud at SMERUD Medical Research Group review the regulatory approaches for compassionate use programmes in the Nordic countries |
|
|
|
| Raimo Tanzi of Applied Biosystems asks 'Is the Cost of Personalised Medicine Really Too High?' in an in-depth focus on the drivers behind the development of these new therapeutics |
|
|
| In Turning on your RADAR: Making your Study Names Recruitment Friendly, Rob Laurens at BBK Worldwide persuades us of the benefits of thinking carefully about what your acronyms are saying about your clinical trials |
|
|
| What are the upcoming industry regulations, who is developing them and how will they affect your company? Find out with Jim Nichols at Thomson Scientific, Liquent Regulatory Solutions in Law and Order |
|
|
|
| If you're thinking of outsourcing, you may be deliberating over the relative benefits of global versus network CROs. John V Farinacci at ResearchPoint provides a helping hand, in Long Distance Relationships: Finding the Right Partner |
|
|
| With talk of India and Latin America as the young pretenders for global clinical trials, where does that leave Central and Eastern Europe? Sue Fitzpatrick of the Institute of Clinical Research looks at the advantages, in CEE No Evil eClinical |
|
|
| With talk of India and Latin America as the young pretenders for global clinical trials, where does that leave Central and Eastern Europe? Sue Fitzpatrick of the Institute of Clinical Research looks at the advantages, in |
|
|
| Integration is happening, and everyone says that they are doing it already, but what does integration in the eClinical industry really mean? Michael Harte and Richard Piazza at etrials provide the answers in Demystifying eClinical Integration |
|
|
| In Get Off at Data Central, Reza Farienfar at Viasys Clinical Services examines how collecting clinical trial data has been revolutionised from an exclusively paper process to centralised data collection as part of EDC, and looks at what it could do for your clinical trials |
|
|
|
| In Taking the Strain Out of Training, Simon Burgess at Zenosis Ltd looks at how on-demand training can help companies stay abreast of regulatory changes |
|
|
| Global trial success depends upon effective multilingual, cross-cultural communications - Gary Muddyman at Conversis reports, in Clinical Trials Across Borders |
|
|
|
| Drug sales may be enormous but the level of unmet medical need for psychiatric and neurodegenerative disorders is alarming; Susan McGoldrick at QCTR Limited investigates in SOS from CNS |
|
|
|
| Attending ICSE this year? Be prepared for The Whole World of Pharmaceutical Outsourcing Under One Roof |
|
|
| DIA Delivers in Philadelphia - yet another successful annual meeting for the Drug Information Association, as this event goes from strength to strength |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder
More info >> |
|
 |
White Papers |
 |
|
Orthogonal Approaches for the Analysis of Protein Sequence
Ludger Ltd
One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
